三元基因 — Investor Relations & Filings
About 三元基因
Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2025年年度报告业绩说明会预告公告 | 2026-04-14 | Chinese | |
| 2025环境、社会及公司治理（ESG）报告 | 2026-04-09 | Chinese | |
| 会计师事务所履职情况评估报告 | 2026-04-09 | Chinese | |
| 2026年度董事、高级管理人员薪酬方案的公告 | 2026-04-09 | Chinese | |
| 申万宏源证券承销保荐有限责任公司关于北京三元基因药业股份有限公司2025年度募集资金存放、管理与实际使用情况的专项核查报告 | 2026-04-09 | Chinese | |
| 关于拟修订《公司章程》公告 | 2026-04-09 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 34846611 | 2025年年度报告业绩说明会预告公告 | 2026-04-14 | Chinese | ||
| 40009040 | 2025环境、社会及公司治理（ESG）报告 | 2026-04-09 | Chinese | ||
| 40008769 | 会计师事务所履职情况评估报告 | 2026-04-09 | Chinese | ||
| 40008766 | 2026年度董事、高级管理人员薪酬方案的公告 | 2026-04-09 | Chinese | ||
| 40008755 | 申万宏源证券承销保荐有限责任公司关于北京三元基因药业股份有限公司2025年度募集资金存放、管理与实际使用情况的专项核查报告 | 2026-04-09 | Chinese | ||
| 40008747 | 关于拟修订《公司章程》公告 | 2026-04-09 | Chinese | ||
| 40008734 | 董事会审计委员会2025年度履职情况报告 | 2026-04-09 | Chinese | ||
| 40008724 | 持股5%以上股东权益变动触及5%整数倍的提示性公告 | 2026-03-05 | Chinese | ||
| 40008716 | 简式权益变动报告书 | 2026-03-05 | Chinese | ||
| 40008702 | 关于公司《药品生产许可证》变更的公告 | 2026-03-01 | Chinese | ||
| 40008692 | 第四届董事会第十二次会议决议公告 | 2026-02-11 | Chinese | ||
| 40008682 | 对外投资暨关联交易公告 | 2026-02-11 | Chinese | ||
| 40008674 | 2025年年度业绩快报公告 | 2026-02-11 | Chinese | ||
| 40008663 | 股票解除限售公告 | 2026-01-29 | Chinese | ||
| 40008654 | 2025年年度业绩预告公告 | 2026-01-28 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
三元基因 via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58807/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58807 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58807 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58807 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58807}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for 三元基因 (id: 58807)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.